Latest on Anabolic Agents for Osteoporosis Treatment

被引：2
|
作者：
di Filippo, Luigi [1 ,2 ]
Rosen, Clifford J. [3 ]
机构：
[1] Univ Vita Salute San Raffaele, Inst Endocrine & Metab Sci, Milan, Italy
[2] IRCCS Osped San Raffaele, Milan, Italy
[3] Main Ehlth Inst Res, Ctr Clin & Translat Res, Scarborough, ME 04074 USA
来源：
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA | 2024年 / 53卷 / 04期
关键词：
Osteoporosis; Anabolics; Teriparatide; Abaloparatide; Romosozumab; Blosozumab; Fragility fractures; Glucocorticoids; PARATHYROID-HORMONE; 1-34; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; DOUBLE-BLIND; ABALOPARATIDE; TERIPARATIDE; ROMOSOZUMAB; FRACTURE; RISK; PLACEBO;
D O I：
10.1016/j.ecl.2024.08.003
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The efficacies of anabolic compounds in preventing fragility fractures and increasing BMD were progressively and widely demonstrated in the last decades. Latest updated clinical data (Table 1) in this setting have markedly downgrading their potential serious side effects including risk of malignancies in teriparatide- and cardiovascular events in romosozumab-users, respectively. Further future data are warranted about their potential efficacy in patients with GIO and, interestingly, their use is currently investigated also in fracture healings setting.
引用
收藏
页码：513 / 523
页数：11
相关论文
共 50 条
  • [11] Polypharmacy in Osteoporosis Treatment
    McConnell, Megan
    Shieh, Albert
    CLINICS IN GERIATRIC MEDICINE, 2022, 38 (04) : 715 - 726
  • [12] Recommendations for the optimal use of bone forming agents in osteoporosis
    Veronese, Nicola
    Briot, Karine
    Guanabens, Nuria
    Albergaria, Ben Hur
    Alokail, Majed
    Al-Daghri, Nasser
    Bemden, Angie Botto-van
    Bruyere, Olivier
    Burlet, Nansa
    Cooper, Cyrus
    Curtis, Elizabeth M.
    Ebeling, Peter R.
    Halbout, Philippe
    Hesse, Eric
    Hiligsmann, Mickael
    Camargos, Bruno Muzzi
    Harvey, Nicholas C.
    Perez, Adolfo Diez
    Radermecker, Regis Pierre
    Reginster, Jean-Yves
    Rizzoli, Rene
    Siggelkow, Heide
    Cortet, Bernard
    Brandi, Maria Luisa
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2024, 36 (01)
  • [13] Anabolic Agents for Postmenopausal Osteoporosis: How Do You Choose?
    Felicia Cosman
    David W. Dempster
    Current Osteoporosis Reports, 2021, 19 : 189 - 205
  • [14] Abaloparatide: Recombinant human PTHrP (1-34) anabolic therapy for osteoporosis
    Chew, Chee Kian
    Clarke, Bart L.
    MATURITAS, 2017, 97 : 53 - 60
  • [15] New anabolic therapies for osteoporosis
    Salvatore Minisola
    Cristiana Cipriani
    Marco Occhiuto
    Jessica Pepe
    Internal and Emergency Medicine, 2017, 12 : 915 - 921
  • [16] Osteoanabolic Agents for Osteoporosis
    Haas, Andrea V.
    LeBoff, Meryl S.
    JOURNAL OF THE ENDOCRINE SOCIETY, 2018, 2 (08): : 922 - 932
  • [17] Romosozumab in the treatment of osteoporosis
    Kobza, Alexandra O.
    Papaioannou, Alexandra
    Lau, Arthur N.
    Adachi, Jonathan D.
    IMMUNOTHERAPY, 2020, 12 (13) : 965 - 981
  • [18] Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis
    Konstantinos A. Toulis
    Athanasios D. Anastasilakis
    Stergios A. Polyzos
    Polyzois Makras
    Hormones, 2011, 10 : 174 - 195
  • [19] One year in review 2018: progress in osteoporosis treatment
    Figliomeni, A.
    Signorini, V.
    Mazzantini, M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (06) : 948 - 958
  • [20] Current approaches to osteoporosis treatment
    Lim, Sian Yik
    Bolster, Marcy B.
    CURRENT OPINION IN RHEUMATOLOGY, 2015, 27 (03) : 216 - 224
12345